Back to Search
MARISA MASTROPASQUA, DO
DO
Family Medicine Physician
NPI: 1861130437IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
DO4127(ME)
CMS Specialties
PrimaryFAMILY PRACTICE
Education
OTHER
Class of 2022
Research & Publications (20)
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.
PMID 19633051·Ann Oncol·2010
4-observational
Hepatic nodules in liver transplantation candidates: MR imaging and underlying hepatic disease.
PMID 15919601·Magn Reson Imaging·2005
8-other
Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast.
PMID 15846389·Mod Pathol·2005
8-other
Cavernous hemangiomas in patients with chronic liver disease: MR imaging findings.
PMID 14972389·Magn Reson Imaging·2004
4-observational
Hoffman's syndrome: muscle stiffness, pseudohypertrophy and hypothyroidism.
PMID 12589116·Horm Res·2003
5-case
Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy.
PMID 19280340·Breast Cancer Res Treat·2010
4-observational
Robotic vs open prostatectomy in a laparoscopically naive centre: a matched-pair analysis.
PMID 19426191·BJU Int·2009
4-observational
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.
PMID 18981464·J Clin Oncol·2008
3-trial
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
PMID 18349391·J Clin Oncol·2008
4-observational
p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer.
PMID 18272916·Ann Oncol·2008
4-observational
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
PMID 18230798·J Natl Cancer Inst·2008
8-other
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
PMID 18083065·Lancet Oncol·2008
3-trial
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
PMID 17679725·J Clin Oncol·2007
3-trial
Sensitivity and detection rate of a 12-core trans-perineal prostate biopsy: preliminary report.
PMID 16426731·Eur Urol·2006
4-observational
Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
PMID 17077359·J Natl Cancer Inst·2006
4-observational
Diagnostic and therapeutic management of carcinoma of unknown primary: histopathological and molecular diagnosis.
PMID 17018717·Ann Oncol·2006
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 7 MAIN RD N
HAMPDEN, ME 04444 - Phone
- (207) 862-9400
Quick Facts
- NPI
- 1861130437
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 4
- Publications
- 20
Are you this provider?
Claim Your Profile